Jyong Biotech (MENS) Competitors $11.78 +0.63 (+5.65%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MENS vs. HCM, IMVT, KYMR, CRNX, MOR, ALVO, RXRX, MIRM, CPRX, and NAMSShould you be buying Jyong Biotech stock or one of its competitors? The main competitors of Jyong Biotech include HUTCHMED (HCM), Immunovant (IMVT), Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Recursion Pharmaceuticals (RXRX), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Jyong Biotech vs. Its Competitors HUTCHMED Immunovant Kymera Therapeutics Crinetics Pharmaceuticals MorphoSys Alvotech Recursion Pharmaceuticals Mirum Pharmaceuticals Catalyst Pharmaceuticals NewAmsterdam Pharma Jyong Biotech (NASDAQ:MENS) and HUTCHMED (NASDAQ:HCM) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Do analysts prefer MENS or HCM? HUTCHMED has a consensus target price of $23.50, suggesting a potential upside of 32.17%. Given HUTCHMED's stronger consensus rating and higher possible upside, analysts clearly believe HUTCHMED is more favorable than Jyong Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00HUTCHMED 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has preferable earnings and valuation, MENS or HCM? HUTCHMED has higher revenue and earnings than Jyong Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJyong BiotechN/AN/AN/AN/AN/AHUTCHMED$630.20M4.92$37.73MN/AN/A Does the media favor MENS or HCM? In the previous week, Jyong Biotech had 3 more articles in the media than HUTCHMED. MarketBeat recorded 6 mentions for Jyong Biotech and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.80 beat Jyong Biotech's score of 0.45 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jyong Biotech 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in MENS or HCM? 8.8% of HUTCHMED shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is MENS or HCM more profitable? Company Net Margins Return on Equity Return on Assets Jyong BiotechN/A N/A N/A HUTCHMED N/A N/A N/A SummaryHUTCHMED beats Jyong Biotech on 7 of the 8 factors compared between the two stocks. Get Jyong Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MENS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MENS vs. The Competition Export to ExcelMetricJyong BiotechPharmaceutical Preparations IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$895.63M$773.27M$2.18B$9.49BDividend YieldN/A4.84%2.58%4.00%P/E RatioN/A1.3822.1319.96Price / SalesN/A24.9393.8982.69Price / CashN/A19.5628.9258.45Price / BookN/A6.8160.265.82Net IncomeN/A-$4.28M-$121.56M$258.42M7 Day Performance6.99%1.99%0.79%1.94%1 Month PerformanceN/A4.61%2.34%12.02%1 Year PerformanceN/A9.43%25.23%20.81% Jyong Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MENSJyong BiotechN/A$11.78+5.7%N/AN/A$895.63MN/A0.0031News CoverageQuiet Period ExpirationHCMHUTCHMED2.8052 of 5 stars$17.74+0.9%$19.00+7.1%-7.0%$3.09B$630.20M0.001,811Analyst ForecastIMVTImmunovant1.0913 of 5 stars$17.70-1.2%$36.30+105.1%-34.3%$3.03BN/A-6.46120Positive NewsKYMRKymera Therapeutics3.1557 of 5 stars$45.14-2.3%$59.11+31.0%+6.8%$2.94B$47.07M-14.56170CRNXCrinetics Pharmaceuticals3.6026 of 5 stars$30.95-0.5%$69.50+124.6%-43.5%$2.90B$1.04M-8.10210Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech2.8685 of 5 stars$8.64+0.1%$16.00+85.2%-22.4%$2.60B$491.98M23.351,032RXRXRecursion Pharmaceuticals0.8993 of 5 stars$6.40+9.6%$7.00+9.4%-25.1%$2.60B$58.84M-3.62400Analyst RevisionHigh Trading VolumeMIRMMirum Pharmaceuticals3.9526 of 5 stars$51.95+0.0%$65.50+26.1%+32.0%$2.57B$336.89M-32.27140Positive NewsCPRXCatalyst Pharmaceuticals4.9136 of 5 stars$21.01-0.1%$32.83+56.3%+22.8%$2.56B$491.73M13.3880News CoveragePositive NewsNAMSNewAmsterdam Pharma3.6333 of 5 stars$22.56+1.6%$41.30+83.1%+26.6%$2.53B$45.56M-12.004 Related Companies and Tools Related Companies HCM Alternatives IMVT Alternatives KYMR Alternatives CRNX Alternatives MOR Alternatives ALVO Alternatives RXRX Alternatives MIRM Alternatives CPRX Alternatives NAMS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MENS) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jyong Biotech Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jyong Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MENS Stock Alerts